search button

Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress

  • Authors:
    • Su‑Fang Zhang
    • Cheng‑Long Xie
    • Jing‑Ya Lin
    • Mei‑Hua Wang
    • Xi‑Jin Wang
    • Zhen‑Guo Liu

  • View Affiliations

  • Published online on: November 6, 2017     https://doi.org/10.3892/mmr.2017.7974
  • Pages: 1118-1124
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Levodopa (L‑DOPA) is the gold standard for symptomatic treatment of Parkinson's disease (PD); however, long‑term therapy is associated with the emergence of L‑DOPA‑induced dyskinesia (LID). Nigral dopaminergic cell loss determines the degree of drug exposure and time required for the initial onset of LID. Accumulating evidence indicates that α‑lipoic acid (ALA) decreases this nigral dopaminergic cell loss. However, until now, the precise mechanisms of ALA have only been partially understood in LID. Chronic L‑DOPA treatment was demonstrated to develop intense AIM scores to assess dyskinetic symptoms. Rats in the LID group were administrated twice daily with L‑DOPA + benserazide for 3 weeks to induce a rat model of dyskinesia. Moreover, other 6‑OHDA‑lesioned rats were treatment with ALA (31.5 mg/kg or 63 mg/kg) in combination with L‑DOPA treatment. Furthermore, the authors investigated the level of malondialdehyde (MDA) and glutathione (GSH) activity, as well as IBa‑1, caspase‑3 and poly (ADP-ribose) polymerase (PARP) in substantia nigra by the way of western blotting and immunofluorescence. ALA reduced LID in a dose‑dependent manner without compromising the anti‑PD effect of L‑DOPA. Moreover, ALA reduced the level of MDA and upregulated the GSH activity, as well as ameliorated IBa‑1 positive neurons in the substantia nigra. Finally, it was identified that ALA could reduce L‑DOPA‑induced cleaved‑caspase‑3 and PARP overexpression in the substantia nigra. Based on the present findings, ALA could be recommended as a promising disease‑modifying therapy when administered with L‑DOPA early in the course of PD. The exact mechanism for this action, although incompletely understood, appears to relate to anti‑oxidative stress and anti‑apoptosis.
View Figures
View References

Related Articles

Journal Cover

January-2018
Volume 17 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 7.6
  • CiteScore Rank: Q1: #82/347 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.647
  • SCImago Journal Rank (SJR): 0.781
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang SF, Xie CL, Lin JY, Wang MH, Wang XJ and Liu ZG: Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress. Mol Med Rep 17: 1118-1124, 2018.
APA
Zhang, S., Xie, C., Lin, J., Wang, M., Wang, X., & Liu, Z. (2018). Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress. Molecular Medicine Reports, 17, 1118-1124. https://doi.org/10.3892/mmr.2017.7974
MLA
Zhang, S., Xie, C., Lin, J., Wang, M., Wang, X., Liu, Z."Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress". Molecular Medicine Reports 17.1 (2018): 1118-1124.
Chicago
Zhang, S., Xie, C., Lin, J., Wang, M., Wang, X., Liu, Z."Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress". Molecular Medicine Reports 17, no. 1 (2018): 1118-1124. https://doi.org/10.3892/mmr.2017.7974